Drug Trial Radar · NCT07299422
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
248
Planned (sponsor's estimate)
Start
Apr 3, 2026
Primary completion
Mar 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Guangdong Hengrui Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, multi-center, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in adult participants with active Systemic Lupus Erythematosus (SLE), including a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and a 12-week safety follow-up period. Approximately 245 SLE patients will be included.
Conditions
- Systemic Lupus Erythematosus
Interventions
SHR-2173 InjectionDrug
SHR-2173 injection in different doses.
SHR-2173 Injection PlaceboDrug
SHR-2173 injection placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of participants achieving Systemic Lupus Erythematosus Responder Index-4 (SRI-4) at Week 24.Time frame: At Week 24.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.